Literature DB >> 21970856

Understanding the dual nature of CD44 in breast cancer progression.

Jeanne M V Louderbough1, Joyce A Schroeder.   

Abstract

CD44 has been the subject of extensive research for more than 3 decades because of its role in breast cancer, in addition to many physiological processes, but interestingly, conflicting data implicate CD44 in both tumor suppression and tumor promotion. CD44 has been shown to promote protumorigenic signaling and advance the metastatic cascade. On the other hand, CD44 has been shown to suppress growth and metastasis. Histopathological studies of human breast cancer have correlated CD44 expression with both favorable and unfavorable clinical outcomes. In recent years, CD44 has garnered significant attention because of its utility as a stem cell marker and has surfaced as a potential therapeutic target, necessitating a greater understanding of CD44 in breast cancer. In this review, we attempt to unify the literature implicating CD44 in both tumor promotion and suppression, and explain its dualistic nature.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21970856     DOI: 10.1158/1541-7786.MCR-11-0156

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  95 in total

Review 1.  Targeting γ-secretase in breast cancer.

Authors:  Jianxun Han; Qiang Shen
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-06-21

2.  Variation and quantification among a target set of phosphopeptides in human plasma by multiple reaction monitoring and SWATH-MS2 data-independent acquisition.

Authors:  Anna M Zawadzka; Birgit Schilling; Jason M Held; Alexandria K Sahu; Michael P Cusack; Penelope M Drake; Susan J Fisher; Bradford W Gibson
Journal:  Electrophoresis       Date:  2014-07-10       Impact factor: 3.535

3.  PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses.

Authors:  Liudmila L Mazaleuskaya; Katrin Sangkuhl; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-08       Impact factor: 2.089

4.  A breast cancer cell microarray (CMA) as a rapid method to characterize candidate biomarkers.

Authors:  Xinyan Wu; Muhammad S Zahari; Santosh Renuse; Harrys K C Jacob; Sruthi Sakamuri; Mukul Singal; Edward Gabrielson; Saraswati Sukumar; Akhilesh Pandey
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

5.  A Three-Dimensional In Vitro Coculture Model to Quantify Breast Epithelial Cell Adhesion to Endothelial Cells.

Authors:  Swathi Swaminathan; Aaron N Cranston; Alisa Morss Clyne
Journal:  Tissue Eng Part C Methods       Date:  2019-09-26       Impact factor: 3.056

6.  Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis.

Authors:  Shin-Ae Kang; Nafis Hasan; Aman P Mann; Wei Zheng; Lichao Zhao; Lynsie Morris; Weizhu Zhu; Yan D Zhao; K Stephen Suh; William C Dooley; David Volk; David G Gorenstein; Massimo Cristofanilli; Hallgeir Rui; Takemi Tanaka
Journal:  Mol Ther       Date:  2015-03-27       Impact factor: 11.454

7.  Tocopherols inhibit estrogen-induced cancer stemness and OCT4 signaling in breast cancer.

Authors:  Min Ji Bak; Philip Furmanski; Naing Lin Shan; Hong Jin Lee; Cheng Bao; Yong Lin; Weichung Joe Shih; Chung S Yang; Nanjoo Suh
Journal:  Carcinogenesis       Date:  2018-07-30       Impact factor: 4.944

8.  Hyaluronan expression in primary and secondary brain tumors.

Authors:  Laurence Jadin; Sandra Pastorino; Rebecca Symons; Natsuko Nomura; Ping Jiang; Tiffany Juarez; Milan Makale; Santosh Kesari
Journal:  Ann Transl Med       Date:  2015-04

9.  Mechanisms Mediating High-Molecular-Weight Hyaluronan-Induced Antihyperalgesia.

Authors:  Ivan J M Bonet; Dionéia Araldi; Eugen V Khomula; Oliver Bogen; Paul G Green; Jon D Levine
Journal:  J Neurosci       Date:  2020-07-14       Impact factor: 6.167

10.  Epithelial Ovarian Cancer and Cancer Stem Cells.

Authors:  Amr A Soliman; Alaa A Elzarkaa; Eduard Malik
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.